Latest ACRIN Cancer Research Group Stories
Researchers at the ECOG-ACRIN Cancer Research Group say comprehensive informed consent is likely the key to preventing undue anxiety over lung screenings. Philadelphia,
Entinostat is being investigated in patients with advanced hormone receptor-positive breast cancer by the ECOG-ACRIN Cancer Research Group in trial E2112. PHILADELPHIA,
Entinostat is being investigated in patients with advanced hormone receptor-positive breast cancer by the ECOG-ACRIN Cancer Research Group in its latest trial, E2112. Philadelphia,
Ibrutinib, a small molecule inhibitor of Bruton’s tyrosine kinase, will be investigated in combination with rituximab by the ECOG-ACRIN Cancer Research Group in its latest clinical trial, E1912.
Blinatumomab, the first BiTE® antibody to be developed for the treatment of cancer, is being investigated by the ECOG-ACRIN Cancer Research Group in its latest trial, E1910. Philadelphia,
An analysis by ECOG-ACRIN researchers shows that TILs are a prognostic factor in women with triple negative breast cancer. San Antonio, TX (PRWEB) December 13,
Results from an ECOG-ACRIN Cancer Research Group trial show the benefit of using the combination of docetaxel and ADT as initial treatment. Philadelphia, PA
18 percent of lung cancers detected by low-dose CT are indolent according to ECOG-ACRIN Cancer Research Group study. Philadelphia, PA (PRWEB) December 09, 2013
- The word or words serving to define another word or expression, as in a dictionary entry.